HOME >> BIOLOGY >> NEWS
What's next for gene therapy? Plastic

Blacksburg, Va., Sept. 13, 2006 -- Gene therapy depends upon foreign DNA, even viruses, to deliver genes, therapeutic proteins, or medicine to cells within the body. Many scientists are looking for better chaperones across the cell membrane. Virginia Tech researchers think polymer molecules can be created to do the job.

The research will be presented at the 232nd national meeting of the American Chemical Society in San Francisco September 10-14, 2006.

"We are applying our fundamental knowledge in polymer science to gene transfer agents," said Tim Long, professor of chemistry in the College of Science at Virginia Tech. "We are trying to understand how the structure of the chaperone impacts the efficiency of its ability to transfer DNA across the cell membrane."

Entire texts have been devoted to the subject, Long said. "But the researchers are usually biologists. Polymer scientists can bring a unique perspective that I think will lead to new advances."

Long's graduate student, John M. Layman of Richmond, Va., will share information regarding star-shaped, or highly-branched, molecules, which are extremely effective at transfection. Long's group has demonstrated that the topology of these particular polymers can be changed. "We can control the molecular shape and number of functional end groups," said Long. "We think that topology is important because it can influence the strength of the interaction with DNA and permit efficient release of the DNA for protein synthesis."

Layman will deliver the talk, "Influence of macromolecular architecture on nucleic acid transfection (POLY 611)," at 4 p.m., Wednesday, Sept. 13, in the Marriott Salon 14/15 as part of the International Biorelated Polymers Symposium. Authors are Layman, Anjali A. Hirani of the Virginia Tech-Wake Forest School of Biomedical Engineering (VT-WF SBES), Joseph M. Pickel and Phillip F. Britt of the Oak Ridge National Laboratory Chemical Sciences Division,
'"/>

Contact: Susan Trulove
STrulove@vt.edu
540-231-5646
Virginia Tech
13-Sep-2006


Page: 1 2

Related biology news :

1. Whats the backscatter of your beer?
2. Whats going on in the body? Advanced time-of-flight PET takes a superior look
3. Whats in the water? Estrogenic activity documented in fish caught in Pittsburghs rivers
4. A Cross-Disciplinary Look at Scientific Truth: Whats the Law to Do?
5. Whats the difference between mice and men?
6. Ossur repeats Popular Science Best of Whats New award
7. Whats shaped like a pear and has two genomes? Check the pond
8. Whats nature worth? New computer models tell all
9. HPV Vaccine: Whats next
10. Anti-evolutionism in AmericaWhats ahead?
11. Ossurs Power Knee wins Popular Science magazines 2005 Best of Whats New Award

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: What next for gene therapy Plastic

(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
(Date:5/20/2015)... 20, 2015 Veracyte, Inc . ... demonstrating the ability of the company,s molecular classifier ... other interstitial lung diseases (ILDs) using samples obtained ... to help thousands of patients avoid invasive, risky ... diagnosis – a frequent challenge for physicians and ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has announced ... Outlook 2020 " report to their offering. ... medicine is expected to have huge marketing potential. Presently, ... the growth of deregulated organs. Several therapeutic molecules are ... form new tissue or sometimes organ transplant is required. ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
Cached News: